AzTrials
AzTrials

Lymphoma, B-CellPhase 2NCT04163302

Safety and Efficiency Study of CD19-PD1-CART Cell in Relapsed/Refractory B Cell Lymphoma

A Phase 2 study testing CD19-PD1-CART Cell in people with Lymphoma, B-Cell, run by Chinese PLA General Hospital at 1 site in China.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

This is a single center, non-randomized, open-label, phase 2 study to evaluate the efficacy and safety of CD19-PD1-CART cells therapy for patients with relapsed/refractory B Cell Lymphoma. Read more about this study

Who is it for?
Ages 14 to 80 years
Conditions the study is for
Lymphoma, B-Cell
What is being tested?
CD19-PD1-CART Cell
Type of treatment
Injection or infusion
Could I receive a placebo?
No, everyone receives an active treatment
How many people
30 participants
Where
1 siteChina
Study dates
7 Jul 2019to 1 Jul 2022
Phase
Phase 2
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 14 to 80 years
  • All sexes
  • No healthy volunteers
  • Child, Adult, Older adult

Who may be able to join

  • Male or female, aged 14 to 80 years (including 14 and 80 years old).
  • The diagnosis was Refractory/relapsed B-cell lymphoma.(Meeting 1 of the first 4 items plus item 5)
  • A.Tumor shrinkage less than 50% or disease progression after 4 cycles of standard chemotherapy.
  • B.Achieved CR after standard chemotherapy, but relapsed within 6 months.
  • C.2 or more relapses after CR.
  • D.Not suitable for HSCT, or relapse after HSCT.
Show all 16Show fewer
  • E.Subjects must have received adequate treatment in the past and the predicted survival is more than three months.
  • Patient or his or her legal guardian voluntarily participates in this stuy and signs an informed consent form.
  • Flow cytometry or immunohistochemistry showed CD19 positive in tumor cells.
  • No serious concomitant disease and major organ function is not serious abnormal.
  • ECOG physical condition score 0-3 or KPS score > 80.
  • the test meets the following indicators:
  • A.ALT/AST < 2.5 times the upper limit of normal (ULN) and total bilirubin≤34.2μmol/L.
  • B.Creatinine < 176.8 μmol/L.
  • C.WBC≥2.5×109/L ，LY≥0.7×109/L，LY%≥15%.
  • D.PT/INR < 1.7 or PT was extended by less than 4 seconds.

Who cannot join

  • Women who are pregnant or breastfeeding.
  • Patients whose tumor cell don't have positive CD19 antigen.
  • Active hepatitis B or hepatitis C, HIV/AIDS infection, any uncontrolled active infection.
  • Patients who are using steroid drugs throughout the body currently.
  • Patients who have received any gene therapy in the past.
  • Patients who are allergy to immunotherapy and related drugs.
Show all 9Show fewer
  • Patients with heavy heart disease or poorly controlled high blood pressure.
  • Patients who received chemotherapy or radiation 4 weeks before the study began.
  • Patients who are participating in other clinical trials.

Trial locations and contacts

1 site in 1 country.

Quanshun Wang contact

15692538521

wqs63@sohu.com

Wenshuai Zheng contact

15701572628

18766179210@163.com

China1 site, 1 recruiting

  • Hai Nan Hospital of Chinese PLA General Hospital

    Sanya, Hainan, 572000

    Wenshuai Zheng, 15701572628, 18766179210@163.com

    Lixun Guan, 15692537637, 15210758157@126.com

    Recruiting

Other trials in China

About this study

This is a single center, non-randomized, open-label, phase 2 study to evaluate the efficacy and safety of CD19-PD1-CART cells therapy for patients with relapsed/refractory B Cell Lymphoma.

Read the detailed description

Lymphoma is a malignant tumor originating from lymph nodes or other lymphoid tissues. It can be divided into B cells, T cells, and NK cell lymphomas depending on the origin of different lymphocytes. Among them, B cell lymphoma accounts for about 90% of lymphoma.

Chimeric antigen receptor T (CART) cells is a promising treatment for lymphoma. T lymphocytes from patients are separated and engineered with CD19-CAR, to specifically recognize and eliminate CD19-positive tumor cells. At present, many CD19CART cells therapy studies are in the stage of clinical research and have achieved significant clinical effects.

Although there are some CD9CART cells clinical trials, the therapeutic effect on lymphoma is significantly lower than that of acute leukemia. One of the reasons is that lymphoma has the nature of solid tumors, whichi has a certain immunosuppressive microenvironment. The clinical trials of anti-PD-1 antibody drugs against lymphoma also show good therapeutic efficacy. Therefore, the combination of anti-PD-1 or PD-L1 antibody and CD19CART is one of the ways to improve the therapeutic effect of CART cells.

The investigators screened PD-1 mutants that have high bind with the PD-L1 ligand, and prepared CD19CART which secretes the mutant PD-1Fc fusion protein. Preclinical studies have shown that CD19CART cells secreting mutant PD-1Fc fusion protein have a superior killing effect to CD19CART cells which does not express PD-1 fusion protein.

The trial was conducted to explore the safety and efficacy of CD19-PD1-CART cells in Relapsed/Refractory B Cell Lymphoma.

Being tested
CD19-PD1-CART Cell
Keywords
Lymphoma, Chimeric antigen receptor T cell, Chimeric antigen receptor, Immunotherapy, PD-1, CD19
Medical subject headings
Lymphoma, B-Cell, Lymphoma

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • CD19-PD1-CART CellBiological

    This study was a single-center, open-label, single-arm, non-randomized clinical trial, which has 3 groups by infusion dose level. Firstly, each dose group has 3 patients. The pretreatment regimen of cyclophosphamide (25mg/m2 for 3 consecutive days) and fludarabine (10mg/kg for 3 consecutive days) was given before CART cells were reinfused. CART cells were reinfused on the third day after the pretreatment. If no serious side effects emerges in the group, then the next group uses the subsequent higher dose. If serious side effects emerges in a single patients in any dose level, 3 more patients will be enrolled to the same dose level. After 9 or more patients, the investigators select the safest dose and recruit more patients for CART test to explore its effectiveness.

Study groups in NCT04163302
Study groupRoleWhat they receive
CD19+ LymphomaExperimentalThis study is to evaluate the efficacy and safety of CD19-PD1-CART cells therapy for patients with Relapsed/Refractory B Cell Lymphoma.
Receives: Biological: CD19-PD1-CART Cell

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Incidence of Treatment-related Adverse Events

    Therapy-related adverse events will be recorded and assessed according to the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE, Version 4.0).

    Measured: 3 years

Secondary outcomes (5)

  1. Overall Remission Rate(ORR) of CD19-PD1-CART cells in Lymphoma

    ORR will be assessed from the first CAR-T cell infusion to death or last follow-up

    Measured: 3 years

  2. Overall survival(OS) of CD19-PD1-CART cells in Lymphoma

    OS will be assessed from the first CAR-T cell infusion to death or last follow-up

    Measured: 3 years

  3. Progress-free survival(PFS) of CD19-PD1-CART cells in Lymphoma

    PFS will be assessed from the first CAR-T cell infusion to death or last follow-up

    Measured: 3 years

  4. Rate of CD19-PD1-CARTcells in peripheral blood cells

    In vivo (peripheral blood) rate of CD19-PD1-CART cells were determined by means of flow cytometry.

    Measured: 3 years

  5. Quantity of CD19-PD1-CART cells copies in peripheral blood cells.

    In vivo (peripheral blood) quantity of CD19-PD1-CART cells copies copies were determined by means of qPCR.

    Measured: 3 years

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted14 Nov 2019
  2. Study start7 Jul 2019
  3. Primary completion1 Jul 2021 (estimated)
  4. Study completion1 Jul 2022 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Model description
This study was a single-center, open-label, single-arm, non-randomized clinical trial, which was divided in 3 groups by different infusion dose level. Firstly, each dose group has 3 patients. The pretreatment regimen of cyclophosphamide (25mg/m2 for 3 consecutive days) and fludarabine (10mg/kg for 3 consecutive days) was given before CART cells were reinfused. CART cells were reinfused on the third day after the pretreatment. If no serious side effects emerges in the group, then the next group uses the subsequent higher dose. If serious side effects emerges in a single patients in any dose level, 3 more patients will be enrolled to the same dose level. After 9 or more patients, the investigators select the safest dose and recruit more patients for CART test to explore its effectiveness.
Masking
None (open label)
Enrolment
30 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04163302
Sponsor's protocol ID
HNYY-XYK-02
Status last verified
Nov 2019
First submitted
12 Nov 2019
Last updated
15 Nov 2019
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing CD19-PD1-CART Cell in people with Lymphoma, B-Cell, run by Chinese PLA General Hospital at 1 site in China.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 16 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 15 Nov 2019. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Quanshun Wang (15692538521, wqs63@sohu.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Incidence of Treatment-related Adverse Events (time frame: 3 years). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04163302.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Nov 2019.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in